BioStock: Oncoinvent in emerging hot spot in oncology

Anders Månsson recently visited BioStock Studio to talk about his new role as CEO of Oncoinvent, a privately held company headquartered in Oslo. The company’s lead candidate is Radspherin, an alpha-radiating radiopharmaceutical developed for the treatment of peritoneal carcinomatosis from colorectal cancer and ovarian cancer. During the interview, Månsson described Radspherin’s mechanism of action and the company’s clinical development plans for the candidate. Furthermore, he shed light on radiopharmaceuticals as an emerging hot spot in oncology attracting great interest from both big pharma and institutional investors.

Watch the interview at biostock.se:

https://www.biostock.se/en/2023/10/oncoinvent-in-emerging-hot-spot-in-oncology/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se